Aspen | Lilly agreement: Aspen announces local availability of Lilly’s Mounjaro ASPEN PHARMACARE HOLDINGS LIMITED Incorporated in the Republic of South Africa ("Aspen Holdings") Registration number: 1985/002935/06 JSE Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries ( collectively "Aspen" or "the Group") Aspen | Lilly agreement: Aspen announces local availability of Lilly's Mounjaro(R) On 30 August 2023, Aspen Holdings ("Aspen") announced that it had entered into a distribution and promotion agreement with Eli Lilly Export S.A. ("Lilly"), to extend access to Lilly's innovative portfolio of medicines to patients in South Africa and the rest of Sub-Saharan Africa. Aspen also confirmed that the pipeline of products includes Lilly's tirzepatide, (marketed in the USA and globally as Mounjaro(R)), a once-weekly glucose-dependent insulinotropic polypeptide ("GIP") receptor and (glucagon-like peptide-1) ("GLP-1") receptor agonist, used as an adjunct to diet and exercise to treat adults with insufficiently controlled Type II diabetes, which has been approved by the South African Health Products Regulatory Authority ("SAHPRA"). Aspen is pleased to announce that Mounjaro(R) will be available in South Africa during the latter part of December 2024 in a single-dose vial, with a KwikPen(R) presentation currently under evaluation at SAHPRA. Tirzepatide is an important addition to the options available to physicians for the treatment of diabetes, particularly as the prevalence of Type II diabetes has doubled in recent times [1] with one in two diabetic patients in our country being undiagnosed [2]. The launch of Mounjaro® will assist in both increasing access and in improving healthcare outcomes. Durban 20 December 2024 Sponsor Investec Bank Limited [1] Stats SA. Non-Communicable diseases in South Africa: Findings from death notifications 2008 – 2018. Available at: https://www.statssa.gov.za/wp-content/uploads/2023/10/Deaths-final.jpg (Accessed 19 December 2024) [2] IDF (2019) Diabetes Atlas - Ninth edition 2019, International Diabetes Federation. Available at: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf (Accessed: 12 November 2024). Date: 20-12-2024 10:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.